CL2023000524A1 - Compuestos fosfolípidos y usos de los mismos - Google Patents
Compuestos fosfolípidos y usos de los mismosInfo
- Publication number
- CL2023000524A1 CL2023000524A1 CL2023000524A CL2023000524A CL2023000524A1 CL 2023000524 A1 CL2023000524 A1 CL 2023000524A1 CL 2023000524 A CL2023000524 A CL 2023000524A CL 2023000524 A CL2023000524 A CL 2023000524A CL 2023000524 A1 CL2023000524 A1 CL 2023000524A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- phospholipid compounds
- phospholipid
- alone
- treatment
- Prior art date
Links
- -1 Phospholipid compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos y métodos para usar dichos compuestos, solos o en combinación con agentes adicionales, y composiciones farmacéuticas de dichos compuestos para el tratamiento de infecciones virales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063069449P | 2020-08-24 | 2020-08-24 | |
US202063092386P | 2020-10-15 | 2020-10-15 | |
US202163151509P | 2021-02-19 | 2021-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023000524A1 true CL2023000524A1 (es) | 2023-09-29 |
Family
ID=77802251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023000524A CL2023000524A1 (es) | 2020-08-24 | 2023-02-22 | Compuestos fosfolípidos y usos de los mismos |
Country Status (16)
Country | Link |
---|---|
US (3) | US11773122B2 (es) |
EP (1) | EP4200301A1 (es) |
JP (1) | JP2023538442A (es) |
KR (1) | KR20230057419A (es) |
CN (1) | CN116323630A (es) |
AU (2) | AU2021330835B2 (es) |
BR (1) | BR112023002951A2 (es) |
CA (1) | CA3188373A1 (es) |
CL (1) | CL2023000524A1 (es) |
CO (1) | CO2023001953A2 (es) |
CR (1) | CR20230100A (es) |
DO (1) | DOP2023000037A (es) |
IL (1) | IL300412A (es) |
MX (1) | MX2023002233A (es) |
TW (2) | TW202337471A (es) |
WO (1) | WO2022046631A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021330835B2 (en) | 2020-08-24 | 2023-12-14 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
EP4355755A1 (en) | 2021-06-14 | 2024-04-24 | Venatorx Pharmaceuticals, Inc. | Orally-bioavailable nucleoside analogs |
WO2023023527A1 (en) * | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
CN115251042B (zh) * | 2022-09-08 | 2023-06-02 | 安徽科技学院 | 一种家禽精液稀释缓冲液及其制备和家禽精液冷存方法 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
DE3778626D1 (de) | 1986-09-27 | 1992-06-04 | Toyo Jozo Kk | Nukleosid-phospholipid-konjugat. |
US7517858B1 (en) | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
ATE385797T1 (de) | 1999-12-03 | 2008-03-15 | Univ California At San Diego | Phosphonatverbindungen |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CA2410488C (en) | 2000-05-26 | 2009-10-27 | Idenix (Cayman) Limited | Methods of treating hepatitis delta virus infection with .beta.-l-2' deoxy-nucleosides |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
EP1646371A4 (en) | 2003-06-26 | 2010-09-22 | Biotron Ltd | ANTIVIRAL COMPOSITIONS AND METHODS |
US8101745B2 (en) | 2004-12-16 | 2012-01-24 | The Regents Of The University Of California | Lung-targeted drugs |
US20090156545A1 (en) | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
SG163517A1 (en) | 2005-06-24 | 2010-08-30 | Biotron Ltd | Antiviral compounds and methods |
CN101827589B (zh) | 2007-08-03 | 2016-08-17 | 拜伊特朗有限公司 | 抗丙型肝炎病毒的组合物及方法 |
WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
EP2342616A2 (en) | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
US9206206B2 (en) | 2008-11-06 | 2015-12-08 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
CN102596949B (zh) | 2009-11-11 | 2015-08-19 | 大日本住友制药株式会社 | 8-氮杂双环[3.2.1]辛烷-8-甲酰胺衍生物 |
US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
BR112014014740B1 (pt) | 2011-12-22 | 2021-08-24 | Alios Biopharma, Inc | Compostos de nucleosídeos, nucleotídeos e análogos destes, seu uso e composição farmacêutica |
EP2892893B2 (en) | 2012-09-10 | 2019-10-16 | F.Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
CA2894542C (en) | 2012-12-21 | 2023-10-31 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
EA032227B1 (ru) | 2013-03-15 | 2019-04-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Сложные диэфиры ациклических нуклеозидфосфонатов |
TW201542578A (zh) | 2013-06-26 | 2015-11-16 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
HUE052856T2 (hu) | 2013-09-11 | 2021-05-28 | Inst Nat Sante Rech Med | Eljárások és gyógyászati készítmények Hepatitis B vírus fertõzés kezelésére |
TW201524990A (zh) | 2013-10-11 | 2015-07-01 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
AU2015212903A1 (en) | 2014-01-30 | 2016-05-19 | F. Hoffmann-La Roche Ag | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection |
LT3114128T (lt) | 2014-03-07 | 2019-03-25 | F. Hoffmann-La Roche Ag | Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai |
RU2016146365A (ru) | 2014-05-13 | 2018-06-19 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b |
CN106573011A (zh) | 2014-06-24 | 2017-04-19 | 艾丽奥斯生物制药有限公司 | 取代的核苷、核苷酸和其类似物 |
AU2015280234B2 (en) | 2014-06-24 | 2021-04-01 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2016012470A1 (en) | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid |
BR112017002970B1 (pt) | 2014-08-14 | 2023-04-11 | F. Hoffmann-La Roche Ag | Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b |
US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
US9676793B2 (en) | 2014-12-23 | 2017-06-13 | Hoffmann-Laroche Inc. | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same |
AR103222A1 (es) | 2014-12-23 | 2017-04-26 | Hoffmann La Roche | Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina |
WO2016107832A1 (en) | 2014-12-30 | 2016-07-07 | F. Hoffmann-La Roche Ag | Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection |
JP2018504891A (ja) | 2014-12-31 | 2018-02-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | リアルタイムPCRによる細胞溶解物からのHBV cccDNA定量化のための新規ハイスループット法 |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
JP2018502604A (ja) | 2015-01-27 | 2018-02-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 組換えHBV cccDNA、その作製方法およびその使用 |
EP3256471B1 (en) | 2015-02-11 | 2018-12-12 | F. Hoffmann-La Roche AG | Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection |
US11963972B2 (en) | 2016-03-23 | 2024-04-23 | Emory University | Antiviral agents and nucleoside analogs for treatment of Zika virus |
MX2019009443A (es) | 2017-02-08 | 2019-12-16 | Biotron Ltd | Metodos para tratar la influenza. |
KR102460968B1 (ko) * | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
JP2020529994A (ja) | 2017-07-31 | 2020-10-15 | ジャニュアリー セラピューティクス,インク. | 有機リン酸誘導体 |
US11149049B2 (en) | 2017-09-18 | 2021-10-19 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2019133712A1 (en) | 2017-12-27 | 2019-07-04 | Schinazi Raymond F | Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents |
JP2021516227A (ja) | 2018-03-02 | 2021-07-01 | ジャニュアリー セラピューティクス,インク. | ナノ粒子組成物 |
TWI791193B (zh) * | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
WO2022020793A1 (en) | 2020-07-24 | 2022-01-27 | The Regents Of The University Of California | Antiviral prodrugs, pharmaceutical formulations, and methods |
AU2021330835B2 (en) | 2020-08-24 | 2023-12-14 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
EP4355755A1 (en) | 2021-06-14 | 2024-04-24 | Venatorx Pharmaceuticals, Inc. | Orally-bioavailable nucleoside analogs |
WO2023023527A1 (en) * | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
-
2021
- 2021-08-23 AU AU2021330835A patent/AU2021330835B2/en active Active
- 2021-08-23 CR CR20230100A patent/CR20230100A/es unknown
- 2021-08-23 JP JP2023513115A patent/JP2023538442A/ja active Pending
- 2021-08-23 BR BR112023002951A patent/BR112023002951A2/pt unknown
- 2021-08-23 US US17/409,261 patent/US11773122B2/en active Active
- 2021-08-23 IL IL300412A patent/IL300412A/en unknown
- 2021-08-23 CN CN202180051637.1A patent/CN116323630A/zh active Pending
- 2021-08-23 CA CA3188373A patent/CA3188373A1/en active Pending
- 2021-08-23 EP EP21772895.5A patent/EP4200301A1/en active Pending
- 2021-08-23 MX MX2023002233A patent/MX2023002233A/es unknown
- 2021-08-23 WO PCT/US2021/047145 patent/WO2022046631A1/en active Application Filing
- 2021-08-23 KR KR1020237009991A patent/KR20230057419A/ko active Search and Examination
- 2021-08-24 TW TW112122916A patent/TW202337471A/zh unknown
- 2021-08-24 TW TW110131250A patent/TWI807399B/zh active
-
2023
- 2023-02-22 DO DO2023000037A patent/DOP2023000037A/es unknown
- 2023-02-22 CL CL2023000524A patent/CL2023000524A1/es unknown
- 2023-02-22 CO CONC2023/0001953A patent/CO2023001953A2/es unknown
- 2023-04-14 US US18/301,179 patent/US20230250117A1/en active Pending
- 2023-06-09 US US18/332,587 patent/US20240025932A1/en active Pending
-
2024
- 2024-03-08 AU AU2024201573A patent/AU2024201573A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230250117A1 (en) | 2023-08-10 |
AU2024201573A1 (en) | 2024-04-04 |
CO2023001953A2 (es) | 2023-03-17 |
WO2022046631A1 (en) | 2022-03-03 |
TW202222323A (zh) | 2022-06-16 |
CR20230100A (es) | 2023-04-28 |
JP2023538442A (ja) | 2023-09-07 |
CN116323630A (zh) | 2023-06-23 |
TWI807399B (zh) | 2023-07-01 |
KR20230057419A (ko) | 2023-04-28 |
US20220081455A1 (en) | 2022-03-17 |
US11773122B2 (en) | 2023-10-03 |
AU2021330835A1 (en) | 2023-03-30 |
BR112023002951A2 (pt) | 2023-03-21 |
IL300412A (en) | 2023-04-01 |
US20240025932A1 (en) | 2024-01-25 |
AU2021330835B2 (en) | 2023-12-14 |
DOP2023000037A (es) | 2023-07-09 |
EP4200301A1 (en) | 2023-06-28 |
MX2023002233A (es) | 2023-03-15 |
CA3188373A1 (en) | 2022-03-03 |
TW202337471A (zh) | 2023-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023002071A2 (es) | Compuestos y métodos para el tratamiento de infecciones virales | |
CL2023000524A1 (es) | Compuestos fosfolípidos y usos de los mismos | |
DOP2022000293A (es) | Análogos de nucleósido de 1-ciano y usos de los mismos | |
CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
CL2023001949A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020) | |
CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
CL2022001719A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
CL2023001062A1 (es) | Compuestos fosfolípidos y usos de estos | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
CO2021010150A2 (es) | Inhibidores irreversibles de la interacción menina-mll | |
UY37741A (es) | Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
SV2007002202A (es) | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan ref. pc32310a | |
CR20180496A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
CO2018009563A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CO2018009559A2 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
CL2019000768A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
CL2009000599A1 (es) | Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras. |